Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant
Tóm tắt
Hairy cell leukemia variant (HCLv) responds poorly to purine analogue monotherapy. Rituximab concurrent with cladribine (CDAR) improves response rates, but long-term outcomes are unknown. We report final results of a phase 2 study of CDAR for patients with HCLv. Twenty patients with 0 to 1 prior courses of cladribine and/or rituximab, including 8 who were previously untreated, received cladribine 0.15 mg/kg on days 1 to 5 with 8 weekly rituximab doses of 375 mg/m2 beginning day 1. Patients received a second rituximab course ≥6 months after cladribine, if and when minimal residual disease (MRD) was detected in blood. The complete remission (CR) rate from CDAR was 95% (95% confidence interval, 75-100). Sixteen (80%) of 20 patients (95% confidence interval, 56-94) became MRD negative according to bone marrow at 6 months. The median duration of MRD-negative CR was 70.1 months, and 7 of 16 are still MRD negative up to 120 months. With a median follow-up of 69.7 months, 11 patients received delayed rituximab, and the 5-year progression-free survival (PFS) and overall survival (OS) were 63.3% and 73.9%, respectively. Five patients with TP53 mutations had shorter PFS (median, 36.4 months vs unreached; P = .0024) and OS (median, 52.4 months vs unreached; P = .032). MRD-negative CR at 6 months was significantly associated with longer PFS (unreached vs 17.4 months; P < .0001) and OS (unreached vs 38.2 months; P < .0001). Lack of MRD in blood at 6 months was also predictive of longer PFS and OS (P < .0001). After progression following CDAR, median OS was 29.7 months. CDAR is effective in HCLv, with better outcomes in patients who achieve MRD-negative CR. This trial is registered at www.clinicaltrials.gov as #NCT00923013.
Tài liệu tham khảo
Xi, 2012, Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation, Blood., 119, 3330, 10.1182/blood-2011-09-379339
Matutes, 2015, Hairy cell leukaemia-variant: disease features and treatment, Best Pract Res Clin Haematol., 28, 253, 10.1016/j.beha.2015.09.002
Matutes, 2001, The natural history and clinico-pathological features of the variant form of hairy cell leukemia, Leukemia., 15, 184, 10.1038/sj.leu.2401999
Robak, 2011, Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment, Cancer Treat Rev., 37, 3, 10.1016/j.ctrv.2010.05.003
Teras, 2016, 2016 US lymphoid malignancy statistics by World Health Organization subtypes, CA Cancer J Clin., 66, 443, 10.3322/caac.21357
Kreitman, 2013, Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia, Clin Cancer Res., 19, 6873, 10.1158/1078-0432.CCR-13-1752
Machii, 2005, Phase II clinical study of cladribine in the treatment of hairy cell leukemia, Int J Hematol., 82, 230, 10.1532/IJH97.04128
Palomera, 2002, Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases, Haematologica., 87, 107
Tetreault, 1999, Treatment of hairy cell leukemia-variant with cladribine, Leuk Lymphoma., 35, 347, 10.3109/10428199909145739
Robak, 1999, 2-Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland, Eur J Haematol., 62, 49, 10.1111/j.1600-0609.1999.tb01114.x
Blasińska-Morawiec, 1997, Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine—a report of three cases, Leuk Lymphoma., 25, 381, 10.3109/10428199709114177
Angelova, 2018, Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience, Mod Pathol., 31, 1717, 10.1038/s41379-018-0093-8
Arons, 2009, VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy, Blood., 114, 4687, 10.1182/blood-2009-01-201731
Hockley, 2011, High-resolution genomic profiling in hairy cell leukemia-variant compared with typical hairy cell leukemia, Leukemia., 25, 1189, 10.1038/leu.2011.47
Chihara, 2016, Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial, Br J Haematol., 174, 760, 10.1111/bjh.14129
Ravandi, 2011, Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia, Blood., 118, 3818, 10.1182/blood-2011-04-351502
Chihara, 2020, Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia, J Clin Oncol., 38, 1527, 10.1200/JCO.19.02250
Sausville, 2003, Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene, Am J Clin Pathol., 119, 213, 10.1309/G6299513NGLCUB1K
Tallman, 1999, Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse, Clin Cancer Res., 5, 1665
Grever, 2017, Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia, Blood., 129, 553, 10.1182/blood-2016-01-689422
Saven, 1998, Long-term follow-up of patients with hairy cell leukemia after cladribine treatment, Blood., 92, 1918, 10.1182/blood.V92.6.1918
Bolger, 2014, Trimmomatic: a flexible trimmer for Illumina sequence data, Bioinformatics., 30, 2114, 10.1093/bioinformatics/btu170
Li, 2009, Fast and accurate short read alignment with Burrows-Wheeler transform, Bioinformatics., 25, 1754, 10.1093/bioinformatics/btp324
McKenna, 2010, The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data, Genome Res., 20, 1297, 10.1101/gr.107524.110
Cibulskis, 2013, Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples, Nat Biotechnol., 31, 213, 10.1038/nbt.2514
Van der Auwera, 2013, From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline, Curr Protoc Bioinformatics., 43, 11.10.11
Lai, 2016, VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research, Nucleic Acids Res., 44, e108, 10.1093/nar/gkw227
McLaren, 2016, The Ensembl Variant Effect Predictor, Genome Biol., 17, 122, 10.1186/s13059-016-0974-4
Kandoth
Shyr, 2014, FLAGS, frequently mutated genes in public exomes [published correction appears in BMC Med Genomics. 2017;10(1):69], BMC Med Genomics., 7, 64, 10.1186/s12920-014-0064-y
Cingolani, 2012, Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift, Front Genet., 3, 35, 10.3389/fgene.2012.00035
Ravandi, 2018, Evaluating measurable residual disease in acute myeloid leukemia, Blood Adv., 2, 1356, 10.1182/bloodadvances.2018016378
Brüggemann, 2017, Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation, Blood Adv., 1, 2456, 10.1182/bloodadvances.2017009845
Thompson, 2016, Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL, Blood., 127, 279, 10.1182/blood-2015-08-634816
Landgren, 2018, MRD testing in multiple myeloma: from a surrogate marker of clinical outcomes to an every-day clinical tool, Semin Hematol., 55, 1, 10.1053/j.seminhematol.2018.03.003
Rosenberg, 2014, Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series, Blood., 123, 177, 10.1182/blood-2013-06-508754
Kreitman, 2018, Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up, Blood., 131, 2331, 10.1182/blood-2017-09-803072
Ortiz-Maldonado, 2018, Is there a role for minimal residual disease monitoring in the management of patients with hairy-cell leukaemia?, Br J Haematol., 183, 127, 10.1111/bjh.14900
Else, 2009, Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis, Br J Haematol., 145, 733, 10.1111/j.1365-2141.2009.07668.x
Muller, 2013, p53 mutations in cancer, Nat Cell Biol., 15, 2, 10.1038/ncb2641
Durham, 2017, Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations, Blood., 130, 1644, 10.1182/blood-2017-01-765107
Rogers, 2021, Phase 2 study of ibrutinib in classic and variant hairy cell leukemia, Blood., 137, 3473, 10.1182/blood.2020009688
Kreitman, 2018, Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia, Leukemia., 32, 1768, 10.1038/s41375-018-0210-1
Herishanu, 2021, Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia, Blood., 137, 3165, 10.1182/blood.2021011568
Grever, 2021, Hairy cell leukemia and COVID-19 adaptation of treatment guidelines, Leukemia., 35, 1864, 10.1038/s41375-021-01257-7